Publikationer

Robust growth expected in 2022

A vast market with growing sales opportunities

Robust output growth expected in 2022

Large backlog of medical treatments to sustain growth in the coming years

Healthy profit margins despite public pressure to lower sales prices

Growing share of generics could affect local producers

Increase in production of primary products planned to lower reliance on China

High days sales outstanding in the wholesalers segment

A major drug production hub with good growth prospects

Business margins expected to increase again in 2022